Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update
by GlobeNewswire
Sep 30, 2024 1:24 pm
- Launched Neurosterix with Perceptive Advisors to accelerate the development of M4PAM for schizophrenia
- Indivior selected GABA B PAM drug candidate for development in substance use disorders
- Addex selected independent GABAB PAM drug candidate for development in chronic cough
Ad Hoc Announcement Pursuant to Art. 53 LR
Register to read this story and more for free.
Signing up for an account helps us improve your browsing experience.
Continue
OR
See our subscription options.
Already have an account? Log in
here